Elena Quaglino

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6296422/publications.pdf

Version: 2024-02-01

61 papers	2,656 citations	201674 27 h-index	182427 51 g-index
62 all docs	62 docs citations	62 times ranked	3765 citing authors

#	Article	IF	Citations
1	DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice. Journal of Immunology, 2000, 165, 5133-5142.	0.8	326
2	Zoledronic acid repolarizes tumourâ€associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. Journal of Cellular and Molecular Medicine, 2010, 14, 2803-2815.	3.6	228
3	microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO Journal, 2011, 30, 1990-2007.	7.8	228
4	Electroporated DNA Vaccine Clears Away Multifocal Mammary Carcinomas in Her-2/neu Transgenic Mice. Cancer Research, 2004, 64, 2858-2864.	0.9	143
5	miR148b is a major coordinator of breast cancer progression in a relapseâ€associated microRNA signature by targeting ITGA5, ROCK1, PIK3CA, NRAS, and CSF1. FASEB Journal, 2013, 27, 1223-1235.	0.5	134
6	Constitutively Active Stat3 Enhances Neu-Mediated Migration and Metastasis in Mammary Tumors via Upregulation of Cten. Cancer Research, 2010, 70, 2558-2567.	0.9	131
7	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. Journal of Clinical Investigation, 2003, 111, 1161-1170.	8.2	105
8	miR-214 Coordinates Melanoma Progression by Upregulating ALCAM through TFAP2 and miR-148b Downmodulation. Cancer Research, 2013, 73, 4098-4111.	0.9	87
9	LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice. Cancer Research, 2003, 63, 2518-25.	0.9	67
10	CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA. Clinical Cancer Research, 2014, 20, 3753-3762.	7.0	64
11	Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. Journal of Clinical Investigation, 2004, 113, 709-717.	8.2	64
12	A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins. Cancer Research, 2010, 70, 2604-2612.	0.9	54
13	miR-135b Coordinates Progression of ErbB2-Driven Mammary Carcinomas through Suppression of MID1 and MTCH2. American Journal of Pathology, 2013, 182, 2058-2070.	3.8	52
14	CSPG4: a prototype oncoantigen for translational immunotherapy studies. Journal of Translational Medicine, 2017, 15, 151.	4.4	51
15	Breast cancer stem cell antigens as targets for immunotherapy. Seminars in Immunology, 2020, 47, 101386.	5.6	48
16	ErbB2 Transgenic Mice: A Tool for Investigation of the Immune Prevention and Treatment of Mammary Carcinomas. Current Protocols in Immunology, 2008, 82, Unit 20.9.1-20.9-10.	3.6	41
17	Combining Human and Rat Sequences in Her-2 DNA Vaccines Blunts Immune Tolerance and Drives Antitumor Immunity. Cancer Research, 2010, 70, 119-128.	0.9	39
18	Ultrasound-activated decafluoropentane-cored and chitosan-shelled nanodroplets for oxygen delivery to hypoxic cutaneous tissues. RSC Advances, 2014, 4, 38433-38441.	3.6	39

#	Article	IF	Citations
19	2H,3H-Decafluoropentane-Based Nanodroplets: New Perspectives for Oxygen Delivery to Hypoxic Cutaneous Tissues. PLoS ONE, 2015, 10, e0119769.	2.5	39
20	The Promise of Preventive Cancer Vaccines. Vaccines, 2015, 3, 467-489.	4.4	38
21	Fighting breast cancer stem cells through the immune-targeting of the xCT cystineâ€“glutamate antiporter. Cancer Immunology, Immunotherapy, 2019, 68, 131-141.	4.2	37
22	DNA vaccination against oncoantigens. OncoImmunology, 2012, 1, 316-325.	4.6	34
23	Naturally occurring cancers in pet dogs as pre-clinical models for cancer immunotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 1839-1853.	4.2	34
24	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogsâ€™ Revolution for Immunotherapy. International Journal of Molecular Sciences, 2018, 19, 799.	4.1	33
25	Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues. Laboratory Investigation, 2015, 95, 561-571.	3.7	30
26	The non-inflammatory role of C1q during Her2/neu-driven mammary carcinogenesis. OncoImmunology, 2016, 5, e1253653.	4.6	30
27	Stat3 is required for anchorageâ€independent growth and metastasis but not for mammary tumor development downstream of the ErbBâ€2 oncogene. Molecular Carcinogenesis, 2010, 49, 114-120.	2.7	29
28	Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers. Frontiers in Oncology, 2013, 3, 122.	2.8	27
29	Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. OncoImmunology, 2013, 2, e26137.	4.6	27
30	Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. Breast Cancer Research, 2014, 16, R10.	5.0	27
31	Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. Journal of Clinical Investigation, 2003, 111, 1161-1170.	8.2	27
32	Immunotargeting of the xCT Cystine/Glutamate Antiporter Potentiates the Efficacy of HER2-Targeted Immunotherapies in Breast Cancer. Cancer Immunology Research, 2020, 8, 1039-1053.	3.4	26
33	Protective Immunity Againstneu-Positive Carcinomas Elicited by Electroporation of Plasmids Encoding Decreasing Fragments of Rat Neu Extracellular Domain. Human Gene Therapy, 2008, 19, 229-240.	2.7	21
34	Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans. Cancers, 2011, 3, 3225-3241.	3.7	21
35	Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers. BMC Genomics, 2014, 15, S1.	2.8	20
36	The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice. Vaccine, 2005, 23, 3280-3287.	3.8	17

#	Article	IF	Citations
37	Immunological prevention of spontaneous tumors: a new prospect?. Immunology Letters, 2002, 80, 75-79.	2.5	16
38	Multiple Roles of Perforin in Hampering ERBB-2 (Her-2/neu) Carcinogenesis in Transgenic Male Mice. Journal of Immunology, 2014, 192, 5434-5441.	0.8	16
39	â€˜In Vitroâ€™, â€˜In Vivoâ€™ and â€˜In Silicoâ€™ Investigation of the Anticancer Effectiveness of Oxygen-Loaded Chitosan-Shelled Nanodroplets as Potential Drug Vector. Pharmaceutical Research, 2018, 35, 75.	3.5	16
40	Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets for Therapy. International Journal of Molecular Sciences, 2021, 22, 2321.	4.1	16
41	Met Receptor Acts Uniquely for Survival and Morphogenesis of EGFR-Dependent Normal Mammary Epithelial and Cancer Cells. PLoS ONE, 2012, 7, e44982.	2.5	16
42	Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. Cancer Immunology, Immunotherapy, 2005, 54, 599-610.	4.2	14
43	Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?. Cancer Immunology, Immunotherapy, 2008, 57, 1685-1694.	4.2	13
44	HER2-based recombinant immunogen to target DCs through FcÎ³Rs for cancer immunotherapy. Journal of Molecular Medicine, 2011, 89, 1231-1240.	3.9	12
45	Antitumor immunization of mothers delays tumor development in cancer-prone offspring. OncoImmunology, 2015, 4, e1005500.	4.6	12
46	Preclinical pharmacokinetics comparison between resveratrol 2-hydroxypropyl-Î²-cyclodextrin complex and resveratrol suspension after oral administration. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2016, 86, 263-271.	1.6	12
47	The rat ErbB2 tyrosine kinase receptor produced in plants is immunogenic in mice and confers protective immunity against ErbB2⁺ mammary cancer. Plant Biotechnology Journal, 2016, 14, 153-159.	8.3	12
48	Cancer stem cell antigens as targets for new combined anti-cancer therapies. International Journal of Biochemistry and Cell Biology, 2020, 129, 105861.	2.8	12
49	Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy. OncoImmunology, 2022, 11, .	4.6	12
50	Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. Current Topics in Microbiology and Immunology, 2014, 405, 99-122.	1.1	10
51	Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2+ mammary cancer. OncoImmunology, 2016, 5, e1082705.	4.6	9
52	Identification of Relevant Conformational Epitopes on the HER2 Oncoprotein by Using Large Fragment Phage Display (LFPD). PLoS ONE, 2013, 8, e58358.	2.5	7
53	Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial. , 2022, 10, e004007.		7
54	Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer. Cancers, 2021, 13, 894.	3.7	6

#	Article	IF	Citations
55	Immunization in tumor prevention. International Immunopharmacology, 2003, 3, 1151-1158.	3.8	4
56	Oncoantigens for an immune prevention of cancer. American Journal of Cancer Research, 2011, 1, 255-264.	1.4	4
57	Role and Involvement of TENM4 and miR-708 in Breast Cancer Development and Therapy. Cells, 2022, 11, 172.	4.1	4
58	HER2-Driven Carcinogenesis: New Mouse Models for Novel Immunotherapies. , 0, , .		3
59	Protection of mice against the highly pathogenic VVIHD-J by DNA and fowlpox recombinant vaccines, administered by electroporation and intranasal routes, correlates with serum neutralizing activity. Antiviral Research, 2016, 134, 182-191.	4.1	3
60	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. Vaccines, 2020, 8, 166.	4.4	1
61	Role of ADCC, CDC, and CDCC in Vaccine-Mediated Protection against Her2 Mammary Carcinogenesis. Biomedicines, 2022, 10, 230.	3.2	1